CN Patent
CN116669797A — 具有护针器的医用注射器
Assigned to Trenta 2 Co · Expires 2023-08-29 · 3y expired
What this patent protects
具有护针器的注射器(1),所述注射器(1)具有通过致动柱塞(4)可在注射器主体(6)内部移动的柱塞(18),其被设计为能够特别有效地输出活性物质,使注射器(1)中未被输出的可能的残留部分最小化。为此,本发明的柱塞(18)具有用于接收注射器针(12)的针座(62),针座(62)的针支座(68)设置在保持夹(66)上,使多个侧向流入表面为自由表面。
USPTO Abstract
具有护针器的注射器(1),所述注射器(1)具有通过致动柱塞(4)可在注射器主体(6)内部移动的柱塞(18),其被设计为能够特别有效地输出活性物质,使注射器(1)中未被输出的可能的残留部分最小化。为此,本发明的柱塞(18)具有用于接收注射器针(12)的针座(62),针座(62)的针支座(68)设置在保持夹(66)上,使多个侧向流入表面为自由表面。
Drugs covered by this patent
- Farxiga (DAPAGLIFLOZIN) · AstraZeneca
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.